New Retina Radio AAO Late-Breakers: ALTITUDE and DIAMOND

RGX-314 (Regenxbio) could be a one-time gene therapy that addresses diabetic retinopathy. How did it perform in the phase 2 ALTITUDE study? Mark Barakat, MD, shares 1-year safety and efficacy findings from the first two dosing levels of RGX-314 in patients with DR. What are the data? And what’s coming next?    And Hani Salehi-Had, MD, joins the show to tell us about the findings in the DIAMOND study, a clinical trial assessing the safety and efficacy of OCS-01 (Oculis), an eye drop designed to treat DME. What did he and his study colleagues find? Keep it here to find out.